ABSTRACT
Successful treatment of peritoneal metastases (PM) requires a comprehensive management plan that utilizes systemic chemotherapy, cytoreductive surgery, and perioperative chemotherapy. Complete resection of all visible malignancy is essential for treatment of peritoneal surface malignancy to result in long-term survival. In general, long-term benefit is expected with low-grade minimally aggressive PM even if the disease extent is extremely large. For high-grade invasive peritoneal metastatic disease, long-term benefit is expected with small extent of disease. The computed tomography scan has been of great help in locating and quantitating mucinous adenocarcinoma within the peritoneal cavity. The recurrences on peritoneal surfaces are nodular and the result of fibrin entrapment of traumatically disseminated sarcoma cells. The most definitive assessment to be used to assess prognosis with peritoneal surface malignancy is the completeness of cytoreduction (CC) score. In both noninvasive and invasive peritoneal surface malignancy, the CC score is the major prognostic indicator.
